All In Biotech

Drug Trial Radar · NCT03778047

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

A Clinical Study for Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Feb 7, 2018

Primary completion

Oct 24, 2018

Study completion Aug 28, 2019

Sponsor

Lead sponsor
Hinova Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study for evaluating enzalutamide pharmacokinetics and pharmacodynamics, and related changes after drug switch in Chinese patients with metastatic castration-resistant prostate cancer. The study primary objective is to evaluate the pharmacokinetic characteristics of enzalutamide in Chinese patients with mCRPC.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • EnzalutamideDrug

    oral

  • HC1119Drug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum drug concentration(Cmax)Time frame: From the first dose of the study drug to 12 weeks after dose
  2. Time of maximum drug concentration(Tmax)Time frame: From the first dose of the study drug to 12 weeks after dose
  3. Area under curve from time 0 to 24h (AUC0-24h)Time frame: From the first dose of the study drug to 12 weeks after dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Ethics Committee of Hunan Cancer Hospital

    Changsha, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.